# Debate prop_0210__mistral-large-4-high__muse-spark-1.3-high__s0__tpl_placement_active_20260813a

- topic_id: prop_0210
- proposition: Countries should require public disclosure of negative clinical trial results as a condition of market access.
- model_pro: mistral-large-4-high
- model_con: muse-spark-1.3-high
- side_swap: False

## Turn 1: PRO Opening

- model: mistral-large-4-high
- raw_words: 313
- clipped_words: 313
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6], [P1.7], [P1.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] Pharmaceutical markets run on information, yet that information is systematically corrupted by selective publication. When companies bring a drug to market, they reap enormous profits from a license to sell, but they routinely bury trials showing the drug fails or harms patients. Doctors then prescribe based on a distorted literature that overstates benefits and hides risks. Every prescription written on incomplete data is a gamble with someone else's health.
[P1.2] This is not a minor academic quibble; it is a public health crisis.
[P1.3] The case for mandatory disclosure as a condition of market access rests on a simple principle: the privilege of selling medicine in a country should require honesty about what that medicine does. Regulators cannot protect citizens if they only see the data sponsors choose to share. When negative trials vanish into file drawers, safety signals disappear. A drug might look effective in published studies while unpublished data reveals dangerous side effects or complete inefficacy.
[P1.4] Patients suffer, health systems waste billions on ineffective treatments, and trust in medicine erodes.
[P1.5] Consider the antidepressant trials in adolescents or the pain medication Vioxx: in both cases, selective reporting obscured risks that harmed real people before regulators intervened. These are not isolated anecdotes but symptoms of a structural incentive problem. Companies have strong financial incentives to highlight successes and minimize failures. Voluntary disclosure has failed; the file drawer problem persists.
[P1.6] Only a binding disclosure requirement can align private profit with public welfare.
[P1.7] Some will claim this burdens innovation, but market access is a conditional privilege, not an entitlement. Countries already impose safety standards, labeling requirements, and manufacturing inspections. Requiring transparency about clinical evidence is simply extending that regulatory logic to the data that determines whether a drug deserves to be on the market at all. Without it, we are not regulating markets; we are subsidizing ignorance.
[P1.8] The alternative is a marketplace where the truth is optional.

## Turn 2: CON Opening

- model: muse-spark-1.3-high
- raw_words: 298
- clipped_words: 298
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7], [C1.8]
- cited_claim_ids: [P1.3]
- missing_claim_id_refs: (none)

[C1.1] Denying sick people an approved medicine because a company failed a public posting rule does not protect patients; it punishes them. That is the perversity of making market access conditional on public disclosure.
[C1.2] Regulators already demand the complete dossier — successes and failures — before approval. The motion is not about keeping secrets from regulators, who in [P1.3] supposedly “only see the data sponsors choose to share.” In modern systems they do not. They see raw datasets, failed trials, safety updates. What PRO demands is something different: compulsory broadcast to the internet as the price of selling at all.
[C1.3] That confusion of regulatory transparency with public dumping is dangerous. A “negative” trial is rarely a clean verdict of failure. Trials miss endpoints because the dose was wrong, the population too narrow, the study underpowered, the comparator mischosen. Experts can interpret that context; frightened patients and rushed headlines cannot.
[C1.4] Dump thousands of ambiguous negative result summaries online and the predictable result is not enlightenment but scaremongering, stopped prescriptions, and eroded adherence — especially for antidepressants, vaccines, and chronic disease drugs where fear already kills compliance.
[C1.5] The penalty makes it worse. If disclosure is the price of market access, a dispute over formatting, timing, or what counts as negative becomes grounds to delay or pull a life-saving drug. Small countries that impose this threat will simply be deprioritized for launch. Companies will file elsewhere first.
[C1.6] Patients wait.
[C1.7] Finally, forced public disclosure is industrial expropriation. Failed trials reveal dosing strategies, biomarker hunches, future indications — the hard-won know-how rivals can mine for free. That tax falls hardest on small biotech firms with one asset, chilling the very research PRO claims to clean up.
[C1.8] More raw data online is not better medicine. Safe regulators with full confidential access, plus continued supply, is.

## Turn 3: PRO Rebuttal 1

- model: mistral-large-4-high
- raw_words: 291
- clipped_words: 291
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7], [P2.8]
- cited_claim_ids: [P1.7], [C1.1], [C1.5], [C1.2], [C1.3], [C1.4], [C1.7]
- missing_claim_id_refs: (none)

[P2.1] The CON case rests on a false choice: that transparency and access must be traded against each other. But market access is a conditional privilege, not an entitlement [P1.7]. When a country says "disclose your negative trials or don't sell here," it is not punishing patients [C1.1]—it is refusing to license a product whose full risk profile remains hidden. The delay CON fears [C1.5] is the mechanism working, not a bug.
[P2.2] If a company withdraws rather than disclose, it reveals exactly the secrecy that endangers patients.
[P2.3] CON claims regulators already see everything [C1.2], so public disclosure is redundant "dumping." This confuses confidential review with accountability. Regulators are fallible; they miss signals, face capture, and cannot monitor every marketed drug indefinitely. Public disclosure creates the independent scrutiny that catches what regulators miss.
[P2.4] Without it, we rely on the same institutions that approved Vioxx and adolescent antidepressants while risks accumulated.
[P2.5] The scaremongering argument [C1.3], [C1.4] is paternalism dressed as protection. Yes, negative trials require context—dose, population, endpoints—but that context belongs in the disclosure, not as a reason to hide the data. Doctors and patients deserve to know when a drug failed to meet its primary endpoint. The alternative is not "calm adherence" but prescriptions written on fiction.
[P2.6] When patients discover—inevitably—that data was hidden, trust collapses. That erosion kills compliance far more than honest disclosure ever could.
[P2.7] Finally, CON calls disclosure "industrial expropriation" [C1.7]. This confuses intellectual property with safety evidence. Failed trial results are not a rival's roadmap to a blockbuster; they are the record of what actually happened to the patients who took the experimental drug. Those patients bore the risk.
[P2.8] The public deserves the results. A company that treats evidence of harm as a trade secret has no business selling medicine.

## Turn 4: CON Rebuttal 1

- model: muse-spark-1.3-high
- raw_words: 298
- clipped_words: 298
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7]
- cited_claim_ids: [P2.1], [P2.3], [P2.5], [P2.7]
- missing_claim_id_refs: (none)

[C2.1] To call blocking an effective medicine 'the mechanism working' [P2.1] confesses what this policy is: holding patients hostage to punish paperwork. Suppose a new cancer or migraine drug clears regulators on full data, benefit outweighing risk, then faces a launch ban because a disclosure form is disputed or a Phase II miss in another dose is posted late. The risk profile is not hidden; regulators saw it. The only people blinded are the sick, who lose months of treatment for a transparency trophy.
[C2.2] That is not protection, it is leverage cruelty.
[C2.3] The fallibility argument proves too much. Yes, regulators err, as with Vioxx. But the fix for fallible experts is better expert check — funded re-analysis, access for qualified researchers under confidentiality — not unfiltered dumping. [P2.3]'s 'independent scrutiny' sounds noble until you ask who actually mines trial registries day to day: plaintiff lawyers hunting warnings to weaponize, competitors hunting designs, headline writers hunting fear.
[C2.4] Busy clinicians do not systematically re-adjudicate thousands of underpowered subgroup misses.
[C2.5] That is why the paternalism charge [P2.5] gets medicine backwards. Context does not travel with a PDF. Once a 'FAILED TRIAL' banner hits search results, adherence among the anxious collapses, especially for antidepressants and vaccines where confidence is already fragile. Prescriptions written on fiction are bad; prescriptions abandoned on confusion are worse.
[C2.6] Nor are negative results mere safety records owed to the public [P2.7]. Most negatives are not hidden harms but efficacy near-misses — wrong dose, wrong endpoint, wrong population — that teach a small biotech where to aim next. Forcing that learning online as the price of selling is a transfer to larger rivals who can afford to copy.
[C2.7] Firms will launch first where rules are proportionate, leaving small countries last in line. Transparency that empties shelves does not serve patients.

## Turn 5: PRO Pressure Questions

- model: mistral-large-4-high
- raw_words: 73
- clipped_words: 73
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C1.7], [C2.3], [P2.4]
- missing_claim_id_refs: (none)

[P3.1] Q1: CON claims negative results reveal "dosing strategies" and "future indications" [C1.7], but a failed trial maps a dead end, not a roadmap to success. How does disclosing what does not work expropriate intellectual property?
[P3.2] Q2: CON proposes "qualified researchers under confidentiality" [C2.3] instead of public disclosure, yet confidential regulators approved Vioxx and missed antidepressant risks [P2.4]. Why trust the same gatekeepers to filter truth when their secret review failed to protect patients?

## Turn 6: CON Pressure Questions

- model: muse-spark-1.3-high
- raw_words: 64
- clipped_words: 64
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: [P2.1]
- missing_claim_id_refs: (none)

[C3.1] Q1: You call blocking an approved drug over paperwork “the mechanism working” [P2.1] — would you deny patients a medicine regulators cleared as safe and effective on full data because a disclosure was late or disputed?
[C3.2] Q2: What exactly counts as “negative” enough to block market access — any missed endpoint, wrong dose, or underpowered trial — and who decides before shelves go empty?

## Turn 7: PRO Rebuttal 2

- model: mistral-large-4-high
- raw_words: 280
- clipped_words: 280
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5], [P4.6], [P4.7]
- cited_claim_ids: [P2.4], [C1.5], [C2.6], [P1.7], [C1.4], [C1.7]
- missing_claim_id_refs: (none)

[P4.1] A1: Yes. A company that refuses to disclose negative results should not sell the drug. That is not "paperwork"—it is the evidence justifying the license. Regulators make provisional judgments; public disclosure is the ongoing audit catching what confidential review misses, as Vioxx demonstrated [P2.4].
[P4.2] Withholding failures while seeking profit is not a right; it is a conflict of interest. The delay is integrity working, not cruelty.
[P4.3] A2: "Negative" means trials failing primary endpoints or revealing significant safety signals—the same dossier regulators weigh for approval. The standard is pre-existing scientific criteria, not ad hoc judgment. If data matters enough to evaluate safety, it matters enough to publish. The regulator decides, applying the same rigor used for the approval decision itself.
[P4.4] CON's entire case protects companies from their own secrecy [C1.5], [C2.6]. But market access is a conditional privilege [P1.7]. When a firm withholds data and forfeits a market, it reveals its product cannot withstand public scrutiny. That is not patients losing medicine; it is patients protected from medicine whose makers fear the truth.
[P4.5] The scaremongering defense [C1.4] collapses against the alternative: prescriptions written on hidden harms. CON asks us to trust gatekeepers who approved Vioxx [P2.4]. We refuse. Sustainable trust is earned through transparency, not enforced through secrecy.
[P4.6] Disclosure aligns private profit with public welfare by making honesty the price of entry.
[P4.7] Countries already condition market access on safety, labeling, and manufacturing standards. Adding clinical transparency is not expropriation [C1.7]; it extends regulatory logic to the data determining whether a drug deserves to exist. The choice is stark: a marketplace where truth is optional, or one where evidence is public. Only the latter protects patients from gambles written on hidden data.

## Turn 8: CON Rebuttal 2

- model: muse-spark-1.3-high
- raw_words: 279
- clipped_words: 279
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5]
- cited_claim_ids: [P4.1], [P4.3]
- missing_claim_id_refs: (none)

[C4.1] A1: A failed trial is rarely just what does not work. A missed dose arm tells a rival which dose to skip and which to test next; a failed broad population with a hint of benefit in a subgroup flags the biomarker to chase; a missed endpoint reveals the design to avoid. For a one-drug biotech, that iterative learning is the company. Broadcasting it as the price of selling hands larger rivals a free R&D shortcut.
[C4.2] A2: Because confidential review failed from too few eyes, not too little panic. The fix is more qualified eyes under confidentiality — independent academics with raw data able to re-analyze — not unfiltered dumping to search engines, plaintiff lawyers, and panic headlines. Vioxx shows experts needed better access sooner; it does not prove anxious teenagers on antidepressants benefit when FAILED TRIAL trends online.
[C4.3] Those answers are why PRO loses. PRO now admits it would deny patients a medicine regulators cleared as safe and effective on full data because a posting was late: "should not sell the drug" [P4.1]. That is not auditing evidence; the evidence was already audited. It is collective punishment where the sick pay for a filing dispute.
[C4.4] And PRO's definition proves the threat is real, not hypothetical. "Failing primary endpoints" [P4.3] sweeps in every underpowered Phase II, wrong-dose exploration, and near-miss that litters normal development. Make that the trigger to block shelves, decided by the same fallible regulator PRO distrusts, and launches will simply go elsewhere first. Small countries get hollow transparency: full registries, empty pharmacies.
[C4.5] Safety comes from regulators with complete dossiers plus researcher scrutiny, with supply intact — not from holding treatment hostage until the internet is satisfied.

## Turn 9: PRO Closing

- model: mistral-large-4-high
- raw_words: 170
- clipped_words: 170
- claim_ids: [P5.1], [P5.2], [P5.3]
- cited_claim_ids: [C2.3], [C2.1]
- missing_claim_id_refs: (none)

[P5.1] This debate asks whether we trust the secrecy that produced Vioxx, or the transparency that could have prevented it. CON offers confidential regulator access plus "qualified researchers under confidentiality" [C2.3]—more gatekeepers, same fallibility. When regulators approved Vioxx and missed adolescent antidepressant risks, the failure was not lack of data but lack of public scrutiny. Only mandatory disclosure creates the independent audit that catches what fallible experts miss.
[P5.2] CON frames blocking non-disclosing companies as "holding patients hostage to punish paperwork" [C2.1], but patients are already hostages to hidden harms. When a firm refuses to publish negative trials, it reveals that its profits depend on ignorance. Market access is a conditional privilege, not an entitlement, and no license to sell should rest on evidence the medical community cannot examine.
[P5.3] The choice is stark: a marketplace where truth is optional, subsidizing gambles written on hidden data, or one where evidence is public and honesty is the price of entry. We cannot protect patients with secrets. We choose evidence over secrecy—and patients over profit.

## Turn 10: CON Closing

- model: muse-spark-1.3-high
- raw_words: 183
- clipped_words: 183
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4], [C5.5], [C5.6], [C5.7]
- cited_claim_ids: [P4.1], [P4.3]
- missing_claim_id_refs: (none)

[C5.1] The question is not whether transparency is good. It is who pays when a posting is late.
[C5.2] PRO answered: patients should. A medicine regulators cleared as safe and effective on full data "should not sell" over a disclosure dispute [P4.1]. The evidence was already audited. The risk profile was already known.
[C5.3] The only people left blind are the sick.
[C5.4] That admission collapses their moral claim. This is not honesty as the price of entry; it is leverage over the wrong hostage. Companies can wait out a ban, file elsewhere, absorb delay. A cancer or migraine patient denied launch cannot.
[C5.5] And the trigger guarantees this cruelty will not be rare. Any missed primary endpoint counts [P4.3] — the normal litter of underpowered explorations, wrong doses, near-misses. Decided by the same regulators PRO calls fallible. Small countries that threaten shelves over footnotes will simply be launched last.
[C5.6] Safety without supply is not protection. Full confidential dossiers plus qualified re-analysis protects, without emptying pharmacies. PRO offers full registries, empty shelves. Patients deserve medicine, not trophies.
[C5.7] Denying cure to enforce candor is not regulation. It is abandonment.
